Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a Buy rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a $4 price target.

March 01, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating and a $4 price target on Arbutus Biopharma.
The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst firm like Chardan Capital could instill confidence among investors and potentially drive the stock price up in the short term. Analyst ratings often influence market perception and investor behavior, especially when they come from well-regarded financial institutions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100